The changing landscape of progressive multifocal leukoencephalopathy

Current Infectious Disease Reports

Volumn 13, Issue 4, 2011, Pages 380-386

  Kedar, Sachin ^a   Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; Chronic lymphocytic leukemia; CLL; Efalizumab; HIV; JC virus; Lymphoma; MS; Multiple sclerosis; Mycophenolate mofetil; Natalizumab; PML; Progressive multifocal leukoencephalopathy; Rheumatoid arthritis; Rituximab; SLE; Systemic lupus erythematosus

Indexed keywords

ALEMTUZUMAB; BELATACEPT; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONNECTIVE TISSUE DISEASE; DISEASE PREDISPOSITION; ENTERITIS; GENETIC VARIABILITY; GRAFT REJECTION; HEMAGGLUTINATION INHIBITION TEST; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INCIDENCE; JC VIRUS; KIDNEY GRAFT REJECTION; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; PATHOGENESIS; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RHEUMATOID ARTHRITIS; SEROPREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIRUS GENE; VIRUS REACTIVATION;

EID: 80052609252     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-011-0196-6     Document Type: Article

References (51)

1. KE Astrom EL Mancall EP Richardson Jr 1958 Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease Brain 81 93 111 13523006 10.1093/brain/81.1.93 1:STN:280:DyaG1c%2FmsF2jsw%3D%3D
2. BL Padgett DL Walker GM ZuRhein, et al. 1971 Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy Lancet 1 7712 1257 1260 4104715 10.1016/S0140-6736(71)91777-6 1:STN:280: DyaE3M3mtVSqug%3D%3D
3. K Dorries 1984 Progressive multifocal leucoencephalopathy: analysis of JC virus DNA from brain and kidney tissue Virus Res 1 25 38 6099652 10.1016/0168-1702(84)90032-7 1:STN:280:DyaL2M7ntVGjsw%3D%3D (Pubitemid 14077364)
4. MC Monaco PN Jensen J Hou, et al. 1998 Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection J Virol 72 9918 9923 9811728 1:CAS:528:DyaK1cXns1Sgu7c%3D (Pubitemid 28520858)
5. JR Berger CS Miller Y Mootoor, et al. 2006 JC virus detection in bodily fluids: clues to transmission Clin Infect Dis 43 e9 12 16758410 10.1086/504947
6. F Taguchi J Kajioka T Miyamura 1982 Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera Microbiol Immunol 26 1057 1064 6300615 1:STN:280:DyaL3s7ms1Kgsg%3D%3D (Pubitemid 13149088)
7. Walker D, Padgett B. The epidemiology of human polyomaviruses. In: Sever J, Madden D, editors. Polyomaviruses and human neurological disease. New York: Alan R. Liss; 1983. p. 99-106.
8. Walker D, Padgett B. Progressive multifocal leukoencephalopathy. In: Fraenkel-Conrat H, Wagner R, editors. Comprehensive virology. New York: Plenum; 1983. p. 161-93.
9. WA Knowles P Pipkin N Andrews, et al. 2003 Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 J Med Virol 71 115 123 12858417 10.1002/jmv.10450 (Pubitemid 37121921)
10. A Matos V Duque S Beato, et al. 2010 Characterization of JC human polyomavirus infection in a Portuguese population J Med Virol 82 494 504 20087944 10.1002/jmv.21710 1:CAS:528:DC%2BC3cXitlKntLo%3D
11. S Wickham B Lu J Ash DJ Carr 2005 Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis J Neuroimmunol 162 51 59 15833359 10.1016/j.jneuroim.2005.01.001 1:CAS:528: DC%2BD2MXjtFyrt7c%3D
12. T Solomon PM Winter 2004 Neurovirulence and host factors in flavivirus encephalitis-evidence from clinical epidemiology Arch Virol Suppl 18 161 170 15119771
13. F Weber C Goldmann M Kramer, et al. 2001 Cellular and humoral immune response in progressive multifocal leukoencephalopathy Ann Neurol 49 636 642 11357954 10.1002/ana.1004 1:CAS:528:DC%2BD3MXjvFKgsr0%3D (Pubitemid 32429790)
14. BL Padgett DL Walker 1973 Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy J Infect Dis 127 467 470 4571704 10.1093/infdis/127.4.467 1:STN:280: DyaE3s7kvVKjtQ%3D%3D
15. JR Berger G Scott J Albrecht, et al. 1992 Progressive multifocal leukoencephalopathy in HIV-1-infected children AIDS 6 837 841 1418781 10.1097/00002030-199208000-00012 1:STN:280:DyaK3s%2FjvFyluw%3D%3D
16. L Gorelik M Lerner S Bixler, et al. 2010 Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 295 303 20737510 10.1002/ana.22128 These authors describe the utility of a two-step assay for identifying patients at risk for developing PML based on the presence of antibodies to the JC virus
17. BR Brooks DL Walker 1984 Progressive multifocal leukoencephalopathy Neurol Clin 2 299 313 6503939 1:STN:280:DyaL2M%2FmtV2ntg%3D%3D
18. JR Berger L Pall D Lanska M Whiteman 1998 Progressive multifocal leukoencephalopathy in patients with HIV infection J Neurovirol 4 59 68 9531012 10.3109/13550289809113482 1:STN:280:DyaK1c7ovFCqtA%3D%3D (Pubitemid 28081579)
19. RM Selik JM Karon JW Ward 1997 Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993 J Infect Dis 176 632 636 9291308 10.1086/514083 1:STN:280: DyaK2svjsFSrtw%3D%3D (Pubitemid 27360526)
20. JR Miller RE Barrett CB Britton, et al. 1982 Progressive multifocal leukoencephalopathy in a male homosexual with T- cell immune deficiency N Engl J Med 307 1436 1438 6290887 10.1056/NEJM198212023072307 1:STN:280: DyaL3s%2Fjs1yksQ%3D%3D (Pubitemid 13234019)
21. LB Krupp RB Lipton ML Swerdlow, et al. 1985 Progressive multifocal leukoencephalopathy: clinical and radiographic features Ann Neurol 17 344 349 4004155 10.1002/ana.410170407 1:STN:280:DyaL2M3itl2iug%3D%3D (Pubitemid 15079060)
22. JR Berger B Kaszovitz MJ Post G Dickinson 1987 Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases Ann Intern Med 107 78 87 3296901 1:STN:280:DyaL2s3jvFOmtA%3D%3D (Pubitemid 17098643)
23. K Kure JF Llena WD Lyman, et al. 1991 Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains Hum Pathol 22 700 710 2071114 10.1016/0046-8177(91)90293-X 1:STN:280:DyaK3MzgtFKmsg%3D%3D
24. W Lang J Miklossy JP Deruaz, et al. 1989 Neuropathology of the acquired immune deficiency syndrome (AIDS): a report of 135 consecutive autopsy cases from Switzerland Acta Neuropathol 77 379 390 2540610 10.1007/BF00687372 1:STN:280:DyaL1M3isFSksA%3D%3D (Pubitemid 19070180)
25. K Kuchelmeister F Gullotta M Bergmann, et al. 1993 Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases Pathol Res Pract 189 163 173 8321744 1:STN:280:DyaK3szhtVWhtA%3D%3D (Pubitemid 23123622)
26. H Bacellar A Munoz EN Miller, et al. 1994 Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985-1992 Neurology 44 1892 1900 7936243 1:STN:280:DyaK2M%2Fit1ajtA%3D%3D (Pubitemid 24319217)
27. JR Berger 2003 Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions J Neurovirol 9 Suppl 1 38 41 12709870 1:CAS:528:DC%2BD3sXksFOqtLc%3D (Pubitemid 36656469)
28. C Singer JR Berger BC Bowen, et al. 1993 Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy Mov Disord 8 113 116 8419794 10.1002/mds.870080120 1:STN:280:DyaK3s7isFGrtA%3D%3D (Pubitemid 23039241)
29. MC Morriss RM Rutstein B Rudy, et al. 1997 Progressive multifocal leukoencephalopathy in an HIV-infected child Neuroradiology 39 142 144 9045978 10.1007/s002340050383 1:STN:280:DyaK2s7pslKrsA%3D%3D (Pubitemid 27075465)
30. SK Shankar P Satishchandra A Mahadevan, et al. 2003 Low prevalence of progressive multifocal leukoencephalopathy in India and Africa: is there a biological explanation J Neurovirol 9 Suppl 1 59 67 12709874 1:CAS:528:DC%2BD3sXksFOrsLo%3D (Pubitemid 36656473)
31. FN Engsig AB Hansen LH Omland, et al. 2009 Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study J Infect Dis 199 77 83 19007313 10.1086/595299
32. KL Christensen RC Holman TA Hammett, et al. 2010 Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005 Neuroepidemiology 35 178 184 20664291 10.1159/000311014
33. KL Amend B Turnbull N Foskett, et al. 2010 Incidence of progressive multifocal leukoencephalopathy in patients without HIV Neurology 75 1326 1332 20938025 10.1212/WNL.0b013e3181f73600 1:STN:280:DC%2BC3cfoslCgsA%3D%3D
34. ES Molloy LH Calabrese 2009 Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases Arthritis Rheum 60 3761 3765 19950261 10.1002/art.24966
35. DB Clifford A De Luca DM Simpson, et al. 2010 Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 438 446 20298967 10.1016/S1474-4422(10) 70028-4 1:CAS:528:DC%2BC3cXltF2ktLg%3D This is an excellent publication describing clinical and radiologic features of PML as well as potential risk-mitigation strategies for the development of PML in patients treated with natalizumab
36. L Kappos D Bates H-P Hartung, et al. 2007 Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Lancet Neurol 6 431 441 17434098 10.1016/S1474-4422(07)70078-9 (Pubitemid 46551850)
37. JR Berger IJ Koralnik 2005 Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences N Engl J Med 353 414 416 15947082 10.1056/NEJMe058122 1:CAS:528:DC%2BD2MXms1Kltbk%3D (Pubitemid 41132348)
38. JR Berger SA Houff EO Major 2009 Monoclonal antibodies and progressive multifocal leukoencephalopathy MAbs 1 583 589 20073129 10.4161/mabs.1.6.9884
39. EO Major 2009 Reemergence of PML in natalizumab-treated patients-new cases, same concerns N Engl J Med 361 1041 1043 19741226 10.1056/NEJMp0906248 1:CAS:528:DC%2BD1MXhtFalt7fO
40. M Lebwohl SK Tyring TK Hamilton, et al. 2003 A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2004 2013 14627785 10.1056/NEJMoa030002 1:CAS:528:DC%2BD3sXptFGnsb8%3D (Pubitemid 37448923)
41. KR Carson AM Evens EA Richey, et al. 2009 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood 113 4834 4840 19264918 10.1182/blood-2008-10-186999 1:CAS:528: DC%2BD1MXmslalsbw%3D
42. F Vincenti C Larsen A Durrbach, et al. 2005 Costimulation blockade with belatacept in renal transplantation N Engl J Med 353 770 781 16120857 10.1056/NEJMoa050085 1:CAS:528:DC%2BD2MXovVKlu70%3D (Pubitemid 41215486)
43. FDA's Cardiovascular and Renal Drugs Advisory Committee: Briefing Document for March 2010 Meeting. Belatacept (BMS-224818). BLA 125288. January 25, 2010. Available at http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm201859.pdf.
44. A Gallamini F Zaja C Patti, et al. 2007 Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood 110 2316 2323 17581918 10.1182/blood-2007-02-074641 1:CAS:528:DC%2BD2sXhtFCnsbzL (Pubitemid 47523150)
45. SI Martin FM Marty K Fiumara, et al. 2006 Infectious complications associated with alemtuzumab use for lymphoproliferative disorders Clin Infect Dis 43 16 24 16758413 10.1086/504811 1:CAS:528:DC%2BD28XntV2ks78%3D
46. EJ Fox 2010 Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis Expert Rev Neurother 10 1789 1797 21091310 10.1586/ern.10.135 1:CAS:528:DC%2BC3cXhsVGktr3F
47. JR Berger 2010 Progressive multifocal leukoencephalopathy and newer biological agents Drug Saf 33 969 983 20925435 10.2165/11537510-000000000-00000 1:CAS:528:DC%2BC3cXhsFaktrjI This review article describes the risks of PML with newer biologic agents, as well as potential risk-mitigation strategies
48. RT Neff FP Hurst EM Falta, et al. 2008 Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation Transplantation 86 1474 1478 19034021 10.1097/TP. 0b013e31818b62c8
49. A Egli L Infanti A Dumoulin, et al. 2009 Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors J Infect Dis 199 837 846 19434930 10.1086/597126 1:CAS:528:DC%2BD1MXktVygtLw%3D
50. GF Elphick W Querbes JA Jordan, et al. 2004 The human polyomavirus, JCV, uses serotonin receptors to infect cells Science 306 1380 1383 15550673 10.1126/science.1103492 1:CAS:528:DC%2BD2cXpvVektL4%3D (Pubitemid 39532516)
51. S Nukuzuma K Nakamichi C Nukuzuma T Takegami 2009 Inhibitory effect of serotonin antagonists on JC virus propagation in a carrier culture of human neuroblastoma cells Microbiol Immunol 53 496 501 19703243 10.1111/j.1348-0421. 2009.00156.x 1:CAS:528:DC%2BC3cXot1Cns7k%3D